India immunology drugs market is expected to grow at a formidable rate during the forecast period. The India immunology drugs market is driven by high prevalence of immunological as well as autoimmune disorders in the country. Additionally, increasing adoption of monoclonal antibody for treating immunological diseases is further expected to boost the demand through FY2026. Improvement in healthcare infrastructure coupled with continuous advancements in drug manufacturing is further predicted to bolster the market growth in the years to come.

The India immunology drugs market is segmented based on drug class, indication, application, company, and region. Based on drug class, the market is segmented into monoclonal antibodies (mAb), antibody drug conjugates, interferon and cytokine therapies, immunosuppressive medication, others. Among them, the monoclonal antibodies segment dominated the market until FY2020 and is further projected to maintain its dominance in the market during the forecast years as well on account of growing research and developmental initiatives in monoclonal antibodies. Also, the immunosuppressive medication segment is anticipated to register high CAGR in the market over the next 5 years which can be accredited to increased revenue for this drug class and high achievement rates in terms of patient treatment.

The major players operating in the India immunology drugs market are Panacea Biotec Ltd., Bristol Myers Squibb India Pvt. Ltd., Wockhardt Ltd., Pfizer Limited, Sanofi India Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Abbott India Ltd., Genentech (Roche) India Pvt. Ltd., Novartis India Ltd., Allergan India Private Limited and others. Major companies are developing advanced technologies, receiving approvals from regulatory bodies, and launching new products in order to stay competitive in the market. Other inorganic growth strategies include mergers & acquisitions, joint ventures, and new product developments in order to sustain themselves amidst fierce competition.

Years considered for this report:

Historical Years: FY2016-FY2019

Base Year: FY2020

Estimated Year: FY2021

Forecast Period: FY2022–FY2026

Objective of the Study:

  • To analyze and estimate the market size of India immunology drugs market from FY2016 to FY2019.
  • To estimate and forecast the market size of India immunology drugs market from FY2020 to FY2026 and growth rate until FY2026.
  • To classify and forecast India immunology drugs market based on drug class, indication, application, company, and regional distribution.
  • To identify dominant region or segment in the India immunology drugs market.
  • To identify drivers and challenges for India immunology drugs market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in India immunology drugs market.
  • To identify and analyze the profile of leading players operating in India immunology drugs market.
  • To identify key sustainable strategies adopted by market players in India immunology drugs market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of India immunology drugs market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.


Key Target Audience:

  • Immunology drugs manufacturers/ suppliers/ distributors
  • Market research and consulting firms
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to immunology drugs

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, India immunology drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • India Immunology Drugs Market, By Drug Class:
    • Monoclonal Antibodies (mAb)
    • Antibody Drug Conjugates
    • Interferon and Cytokine Therapies
    • Immunosuppressive Medication
    • Others
  • India Immunology Drugs Market, By Indication:
    • In- Arthritis
    • Plaque Psoriasis
    • Spondylitis
    • Inflammatory Bowel Disease
    • Transplant Rejection
    • Others
  • India Immunology Drugs Market, By Application:
    • Hospitals
    • Clinics
    • Cancer Research Institute
    • Others
  • India Immunology Drugs Market, By Region:
    • North
    • South
    • East
    • West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in India immunology drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
India immunology drugs market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]  

1.    Product Overview

2.    Research Methodology

3.    Executive Summary

4.    Impact of COVID-19 on India Immunology Drugs Market

5.    Voice of Customer

6.    India Immunology Drugs Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Drug Class (Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication, Others)

6.2.2.     By Indication (Arthritis, Plaque Psoriasis, Spondylitis, Inflammatory Bowel Disease, Transplant Rejection, Others)

6.2.3.     By Application (Hospitals, Clinics, Cancer Research Institute, Others)

6.2.4.     By Company (2020)

6.2.5.     By Region

6.3.  Product Market Map

7.    North India Immunology Drugs Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Drug Class

7.2.2.     By Indication

7.2.3.     By Application

8.    South India Immunology Drugs Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Drug Class

8.2.2.     By Indication

8.2.3.     By Application

9.    East India Immunology Drugs Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Drug Class

9.2.2.     By Indication

9.2.3.     By Application

10.  West India Immunology Drugs Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Drug Class

10.2.2.  By Indication

10.2.3.  By Application

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

13.  Competitive Landscape

13.1.              Company Profiles

13.1.1.  Panacea Biotec Ltd.

13.1.2.  Bristol Myers Squibb India Pvt. Ltd.

13.1.3.  Wockhardt Ltd.

13.1.4.  Pfizer Limited

13.1.5.  Sanofi India Ltd.

13.1.6.  GlaxoSmithKline Pharmaceuticals Ltd.

13.1.7.  Abbott India Ltd.

13.1.8.  Genentech (Roche) India Pvt. Ltd.

13.1.9.  Novartis India Ltd.

13.1.10.                Allergan India Private Limited

14.  Strategic Recommendations

About Us & Disclaimer